Physician profile
Sun Qiu
NPI 1427586379
$5,864.00
in general payments reported to CMS, 2019-2025
49 companies · $2,044 in 2025
The $2,044 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2022: $256 · 2023: $1,316 · 2024: $2,119 · 2025: $2,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,328 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,328.09 |
| Education | $152.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $684.35 | 2022-2025 | |
| Ucb, INC. | $614.67 | 2022-2025 | Briviact, Nayzilam, Rystiggo |
| Novartis Pharmaceuticals Corporation | $420.70 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $351.25 | 2023-2025 | Ultomiris, Soliris |
| Pfizer INC. | $308.18 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $298.45 | 2024-2025 | Rexulti |
| Biogen, INC. | $283.57 | 2022-2025 | Tysabri, Vumerity, Leqembi |
| Sk Life Science, INC. | $232.61 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $229.47 | 2022-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $224.94 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $214.36 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Lilly USA, LLC | $192.83 | 2023-2025 | Emgality, Kisunla, Amyvid |
| Argenx US, INC. | $143.56 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $129.68 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $125.29 | 2024-2025 | Nuplazid, Daybue |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $122.77 | 2022-2025 | |
| Lundbeck LLC | $98.53 | 2023-2024 | Vyepti |
| Tg Therapeutics, INC. | $92.34 | 2024-2025 | |
| Genentech USA, INC. | $91.18 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Neurelis, INC. | $72.86 | 2023-2024 | Valtoco |
| Kyowa Kirin, INC. | $64.85 | 2022-2024 | Nourianz |
| Janssen Biotech, INC. | $57.76 | 2025 | |
| Amgen INC. | $54.85 | 2022-2024 | Uplizna |
| Vanda Pharmaceuticals INC. | $52.46 | 2024-2025 | Ponvory |
| Avion Pharmaceuticals | $49.90 | 2022-2023 | Dhivy |
| Alnylam Pharmaceuticals INC. | $49.51 | 2023-2024 | Amvuttra, Onpattro |
| Axsome Therapeutics, INC. | $49.38 | 2025 | Symbravo |
| Mdd US Operations, LLC | $48.55 | 2024 | Gocovri |
| Celgene Corporation | $43.00 | 2023-2025 | Zeposia |
| Cycle Pharmaceuticals INC | $38.98 | 2024-2025 | Tascenso Odt |
| Impel Pharmaceuticals INC. | $37.94 | 2023 | Trudhesa |
| Amneal Pharmaceuticals LLC | $30.87 | 2024-2025 | Crexont, Rytary |
| Acorda Therapeutics, INC | $28.83 | 2024 | Inbrija |
| Corium, LLC | $26.38 | 2023 | Adlarity |
| Harmony Biosciences LLC | $26.14 | 2023 | Wakix |
| Forte Bio-Pharma LLC | $26.02 | 2025 | Tanlor |
| Mallinckrodt Hospital Products INC. | $25.35 | 2022 | |
| Banner Life Sciences, LLC | $23.49 | 2023 | |
| Kedrion Biopharma, INC. | $22.24 | 2024 | Koate, Albuked, Kedrab |
| Tanabe Pharma America, INC. | $20.14 | 2023 | |
| Csl Behring | $20.13 | 2023 | Hizentra |
| Azurity Pharmaceuticals, INC. | $19.16 | 2025 | Horizant |
| Horizon Therapeutics Plc | $19.00 | 2023 | Uplizna |
| Ani Pharmaceuticals, INC. | $18.94 | 2023 | Purified Cortrophin Gel |
| Scilex Pharmaceuticals INC. | $18.73 | 2024 | |
| Cala Health, INC. | $17.63 | 2023 | Cala Trio |
| Impel Pharmaceuticals LLC | $16.33 | 2025 | Trudhesa |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.18 | 2022 | |
| Collegium Pharmaceutical, INC. | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sun Qiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.